A biomarker panel for IPF may identify RA patients at higher risk for ILD, supporting biological overlap between IPF and RA-ILD. The study involved over 2500 US veterans and showed strong associations ...
Antifibrotic treatments have similar effects in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Despite the development of cutting-edge genetic testing techniques and considerable progress in our understanding of the genetic basis of idiopathic pulmonary fibrosis (IPF), missing heritability and ...
According to a new study, the score can accurately predict long-term outcomes in patients with IPF and ILD associated with connective tissue disease.
The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...
Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...
Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...
-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results